Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis

Journal of the American Society of Nephrology

Volumn 28, Issue 9, 2017, Pages 2756-2767

  Jayne, David R W ^a   Bruchfeld, Annette N ^b   Harper, Lorraine ^c   Schaier, Matthias ^d   Venning, Michael C ^e   Hamilton, Patrick ^e   Burst, Volker ^f   Grundmann, Franziska ^f   Jadoul, Michel ^g   Szombati, István ^h   Tesar, Vladimír ⁱ   Segelmark, Marten ^j   Potarca, Antonia ^k   Schall, Thomas J ^k   Bekker, Pirow ^k  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h Budai Irgalmasrendi Korhaz ^*  (Hungary)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j LINKÖPING UNIVERSITY   (Sweden)

^k ChemoCentryx Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVACOPAN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; ANILINE DERIVATIVE; C5AR1 PROTEIN, HUMAN; COMPLEMENT COMPONENT C5A RECEPTOR; IMMUNOSUPPRESSIVE AGENT; NIPECOTIC ACID DERIVATIVE;

ADULT; AMNESIA; ANCA ASSOCIATED VASCULITIS; ANXIETY DISORDER; ARTICLE; BACKACHE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CONVULSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; INSOMNIA; KIDNEY DISEASE; LYMPHOCYTOPENIA; MALE; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; MIDDLE AGED; MOOD DISORDER; MULTICENTER STUDY; NEURITIS; NEUROPATHY; PARESTHESIA; PERSONALITY DISORDER; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SCHIZOPHRENIA; SCORING SYSTEM; SPINE FRACTURE; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS; VERTIGO; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANILINE COMPOUNDS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NIPECOTIC ACIDS; PREDNISONE; RECEPTOR, ANAPHYLATOXIN C5A; RITUXIMAB; SEVERITY OF ILLNESS INDEX;

EID: 85028646927     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016111179     Document Type: Article

References (38)

1. Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D, Jayne D,Morishita K, Arden N:Mortality in Wegener's granulomatosis: A bimodal pattern. Rheumatology (Oxford) 50: 697-702, 2011
2. LittleMA,Nightingale P, VerburghCA,Hauser T,DeGroot K, SavageC, Jayne D, Harper L; European Vasculitis Study (EUVAS) Group: Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69: 1036-1043, 2010
3. Jayne D: Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 39: 585-595, 2000
4. KoldingsnesW,Nossent H: Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 41: 572-581, 2002
5. Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL: Overall survival, renal survival and relapse in patients with microscopic polyangiitis: A systematic review of current evidence. Rheumatology (Oxford) 50: 1414-1423, 2011
6. Takala JH, Kautiainen H, Finne P, Leirisalo-Repo M: Wegener's granulomatosis in Finland in 1981-2000: Risk of dialysis-dependent renal disease. Scand J Rheumatol 40: 283-288, 2011
7. Mohammad AJ, Segelmark M: A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCAassociated nephritis. J Rheumatol 41: 1366-1373, 2014
8. Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L: Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 68: 658-663, 2009
9. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH: Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7: 240-247, 2012
10. Goupil R, Brachemi S, Nadeau-Fredette A-C, Déziel C, Troyanov Y, Lavergne V, Troyanov S: Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8: 416-423, 2013
11. Robson J, Doll H, Suppiah R, FlossmannO, Harper L, Höglund P, Jayne D, Mahr A, Westman K, Luqmani R: Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-termdata fromthe European Vasculitis StudyGroup trials. Rheumatology (Oxford) 54: 471-481, 2015
12. Halbwachs L, Lesavre P: Endothelium-neutrophil interactions in ANCAassociated diseases. J Am Soc Nephrol 23: 1449-1461, 2012
13. Furuta S, Jayne DR: Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments. Kidney Int 84: 244-249, 2013
14. Kettritz R: With complements from ANCA mice. J Am SocNephrol 25: 207-209, 2014
15. Schreiber A, Xiao H, Jennette JC, SchneiderW, Luft FC, Kettritz R: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20: 289-298, 2009
16. Camous L, Roumenina L, Bigot S, Brachemi S, Frémeaux-Bacchi V, Lesavre P, Halbwachs-Mecarelli L: Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117: 1340-1349, 2011
17. Hammerschmidt DE, Harris PD, Wayland JH, Craddock PR, Jacob HS: Complement-induced granulocyte aggregation in vivo. Am J Pathol 102: 146-150, 1981
18. Tse WY, Nash GB, Hewins P, Savage COS, Adu D: ANCA-induced neutrophil F-actin polymerization: Implications for microvascular inflammation. Kidney Int 67: 130-139, 2005
19. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, GlovskyMM, Eddy SM,Ward PA: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 94: 1147-1155, 1994
20. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R: Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169: 2102-2110, 2002
21. Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T,Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ: Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoSOne 11: e0164646, 2016
22. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, PenfoldMET,Gan L, Hu P, Lu B, GerardNP,GerardC, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225-231, 2014
23. Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235-238, 1979
24. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis.NEngl J Med363: 221-232, 2010
25. Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune ToleranceNetwork ResearchGroup:Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65: 2441-2449, 2013
26. Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A: Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18[Suppl 5]: v5-v7, 2003
27. Stangou M, Asimaki A, BamichasG,Christidou F, ZoumbaridisN, Natse T, Galanis N, Christaki P, Patakas D, Sombolos K: Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: A single-center experience. J Nephrol 18: 35-44, 2005
28. Tam FWK, Sanders J-S, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD: Urinary monocyte chemoattractant protein-1 (MCP-1) is amarker of active renal vasculitis. Nephrol Dial Transplant 19: 2761-2768, 2004
29. Tesch GH: MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.AmJ Physiol Renal Physiol 294: F697-F701, 2008
30. Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS: Association of urinary inflammatorymarkers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 19: 789-797, 2008
31. Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG: Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial. Clin J Am Soc Nephrol 11: 1343-1352, 2016
32. Zheng D,WolfeM, Cowley BDJr.,Wallace DP, Yamaguchi T,Grantham JJ: Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588-2595, 2003
33. Pountain GD, Keogan MT, Hazleman BL, Brown DL: Effects of single dose compared with three days' prednisolone treatment of healthy volunteers: Contrasting effects on circulating lymphocyte subsets. J Clin Pathol 46: 1089-1092, 1993
34. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433-439, 2000
35. Flossmann O, Baslund B, Bruchfeld A, Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DRW: Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 68: 1125-1130, 2009
36. Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010
37. Yates M,Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçindag N, Jayne DR, Mukhtyar C: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75: 1583-1594, 2016
38. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlledclinical trial.Biometrics 31: 103-115, 1975